Determine the feasibility of concurrent cetuximab and chemoradiation as measured by safety and compliance. Safety is measured by the rate of grade 3 or worse nonhematological toxicities occurring prior to the beginning of consolidation therapy (including

Histologically or cytologically documented NSCLC; Patients must be MO. Patients with T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients withT4 with any N or any T with N2 or N3 disease are eligible if unresectable.